Peter A Kaufman MD
Breast Cancer, Hematologic Oncology
Associate Professor of Medicine, Dartmouth Medical School
Join to View Full Profile
Beaumont AveUVM Cancer CenterBurlington, VT 05403
Phone+1 603-653-6181
Dr. Kaufman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1989- Duke University HospitalResidency, Internal Medicine, 1983 - 1986
New York University School of MedicineClass of 1983
Certifications & Licensure
VT State Medical License 1993 - 2026
NH State Medical License 1992 - 2020
NC State Medical License 1987 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- BIO25-024: Real-Time Clinical Trial Data Library in Non-Small Cell Lung (NSCLC), Prostate (PC), and Breast Cancer (BC) to Support Informed Treatment Decisions: Now a R...Rozee Junhan Liu, Anna Forsythe, Jessicca Martin Rege, Peter Kaufman
Journal of the National Comprehensive Cancer Network. 2025-03-28 - 5 citationsAbemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park
Journal of Clinical Oncology. 2025-03-20 - 4 citationsImlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Grow...Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton
Journal of Clinical Oncology. 2024-12-10
Press Mentions
Breast Cancer: What We Know TodayJune 2nd, 2022- Laekna Therapeutics Announces Dosing of First Patients in the U.S. And China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast CancerMay 26th, 2022
- UVM Students Contribute to Groundbreaking Cancer ResearchJune 9th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
